Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis

Arthritis Care and Research

Volumn 61, Issue 11, 2009, Pages 1484-1490

  De Vries, Mirjam K ^a   Van Eijk, Izhar C ^b   Van Der Horst Bruinsma, Irene E ^a   Peters, Mike J L ^a   Nurmohamed, Michael T ^a   Dijkmans, Ben A C ^a   Hazenberg, Bouke P C ^c   Wolbink, Gerrit J ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE MARKER; DRUG MONITORING; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; PREDICTION; PROTEIN BLOOD LEVEL; RATING SCALE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DRUG MONITORING; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SERUM AMYLOID A PROTEIN; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449516048     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24838     Document Type: Article

References (21)

1. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-2291
2. Berthelot JM, Tortellier L, Lavy-Bregeon D, Le Goff B, Maugars Y. High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFα antagonist therapy for spondyloarthropathies? Joint Bone Spine 2008;75:167-171
3. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999;26:966-970 (Pubitemid 29195695)
4. Jung SY, Park MC, Park YB, Lee SK. Serum amyloid A as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J 2007;48:218-224 (Pubitemid 46711751)
5. Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 2007;74:249-253 (Pubitemid 46720043)
6. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-984 (Pubitemid 29195698)
7. Yildirim K, Erdal A, Karatay S, Melikoglu MA, Ugur M, Senel K. Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J 2004;97:350-353 (Pubitemid 38478751)
8. Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S, et al. C-reactive protein predicts tumor necrosis factor-α blocker retention rate in axial ankylosing spondylitis. J Rheumatol 2007;34:2078-2081 (Pubitemid 47548214)
9. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-670 (Pubitemid 38658395)
10. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1994;1:119-137 (Pubitemid 2100716)
11. Uhlar CM, Whitehead AS. The kinetics and magnitude of the synergistic activation of the serum amyloid A promoter by IL-1 β and IL-6 is determined by the order of cytokine addition. Scand J Immunol 1999;49:399-404.
12. Lange U, Boss B, Teichmann J, Klor HU, Neeck G. Serum amyloid A: an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 2000;19:119-122 (Pubitemid 30242746)
13. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368 (Pubitemid 14134775)
14. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452
15. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-824 (Pubitemid 37026490)
16. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-320 (Pubitemid 43268219)
17. Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH. Monoclonal antibody based ELISA for human SAA. In: Natvig JB, Forre O, Husby G, Husebekk A, Skogen B, Sletten K, et al, editors. Amyloid and amyloidosis. Dordrecht (The Netherlands): Kluwer Academic; 1991. p. 898-901.
18. De Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation [letter]. Ann Rheum Dis 2007;66:133-134 (Pubitemid 46044875)
19. Sellmayer A, Limmert T, Hoffmann U. High sensitivity C-reactive protein in cardiovascular risk assessment: CRP mania or useful screening? Int Angiol 2003;22:15-23.
20. Gerard S, Le Goff B, Maugars Y, Berthelot JM. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New York criteria for ankylosing spondylitis or French recommendations for anti-TNF use: a "real life" retrospective study on 175 patients. Joint Bone Spine 2008;75:680-687
21. De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231-234